ライフサイエンスコーパス: autologous stem cell transplantation

1 ither on their own or as graft complement in autologous stem cell transplantation.

2 ne and rituximab as induction regimen before autologous stem cell transplantation.

3 ne therapy) or relapsed at </=12 months from autologous stem cell transplantation.

4 rapy for patients eligible or ineligible for autologous stem cell transplantation.

5 or R-DHAP followed by high-dose therapy and autologous stem cell transplantation.

6 multiagent chemotherapy regimens followed by autologous stem cell transplantation.

7 gamma production is markedly defective after autologous stem cell transplantation.

8 or younger who are potential candidates for autologous stem cell transplantation.

9 and peritoneal cancer, as well as following autologous stem cell transplantation.

10 f shiga toxin as an ex vivo purging agent in autologous stem cell transplantation.

11 ment with conventional high-dose therapy and autologous stem cell transplantation.

12 ving other lymphodepleting therapies such as autologous stem cell transplantation.

13 high-dose melphalan chemotherapy followed by autologous stem cell transplantation.

14 r high-dose therapy and either allogeneic or autologous stem cell transplantation.

15 cal samples after high-dose chemotherapy and autologous stem cell transplantation.

16 atients were permitted to come off study for autologous stem cell transplantation.

17 located between whole-brain radiotherapy and autologous stem cell transplantation.

18 incorporated into intensive strategies with autologous stem cell transplantation.

19 come that may deserve intensive salvage with autologous stem cell transplantation.

20 of prior therapy, and 71% had relapsed after autologous stem cell transplantation.

21 kin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation.

22 ing treatment for myeloma with melphalan and autologous stem cell transplantation.

23 d thus it is often followed by consolidative autologous stem cell transplantation.

24 ondary malignancies, and planning for future autologous stem cell transplantation.

25 /=65 years of age or who were ineligible for autologous stem cell transplantation.

26 ne (PAD) followed by high-dose melphalan and autologous stem-cell transplantation.

27 ly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation.

28 (range, one to seven), and 73% had undergone autologous stem-cell transplantation.

29 h a positive biopsy received ICE followed by autologous stem-cell transplantation.

30 with second-line chemotherapy/radiation and autologous stem-cell transplantation.

31 egimens, and 17 patients had undergone prior autologous stem-cell transplantation.

32 antibody gemtuzumab ozogamicin, followed by autologous stem-cell transplantation.

33 d experienced treatment failure with a prior autologous stem-cell transplantation.

34 atients relapsed after high-dose therapy and autologous stem-cell transplantation.

35 rly for patients who are eligible to receive autologous stem-cell transplantation.

36 latin, and carmustine (STAMP-I), followed by autologous stem-cell transplantation.

37 psed patients received high-dose therapy and autologous stem-cell transplantation.

38 t therapeutic option for patients undergoing autologous stem-cell transplantation.

39 g per square meter of body-surface area) and autologous stem-cell transplantation.

40 ival when given as early consolidation after autologous stem-cell transplantation.

41 identified, 107 with allogeneic and 144 with autologous stem-cell transplantation.

42 e two study groups among patients undergoing autologous stem-cell transplantation.

43 second-line therapy in either arm, including autologous stem-cell transplantation.

44 85 (80%) patients had previously received autologous stem cell transplantation, 101 (95%) were ref

45 ance therapy or to undergo observation after autologous stem-cell transplantation (120 patients per g

46 en May 2002 and January 2006, 14 days before autologous stem-cell transplantation, 41 patients with n

47 e inhibitors (91%), alkylating agents (91%), autologous stem cell transplantation (78%), thalidomide

48 We have assessed autologous stem cell transplantation after treatment wit

49 We conclude that chemotherapy or autologous stem-cell transplantation after prior therapy

50 eceded by surgical resection and followed by autologous stem cell transplantation, although biologic

51 These patients receive minimal benefit from autologous stem cell transplantation and are candidates

52 f pPCL has improved with the introduction of autologous stem cell transplantation and combination app

53 ith lenalidomide maintenance treatment after autologous stem cell transplantation and one study after

54 or regimens (range, 2-6 regimens), including autologous stem cell transplantation and Thal in 15 and

55 , perihilar infiltrates, and hypoxemia after autologous stem cell transplantation and the use of reco

56 olled in the study after a relapse following autologous stem-cell transplantation and 78% after a rel

57 cal Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab ved

58 ical Hodgkin's lymphoma who progressed after autologous stem-cell transplantation and brentuximab ved

59 ecommended for pediatric patients undergoing autologous stem-cell transplantation and for adult and p

60 gkin's lymphoma who had failed to respond to autologous stem-cell transplantation and had either rela

61 e resource for stem-cell therapies including autologous stem-cell transplantation and tissue engineer

62 myloidosis has made less certain the role of autologous stem cell transplantation, and new quantitati

63 All patients received HDCT with autologous stem-cell transplantation, and 41 patients re

64 age, Mayo Clinic AL amyloidosis stage, prior autologous stem-cell transplantation, and difference bet

65 ated with high-dose chemotherapy followed by autologous stem-cell transplantation, and four patients

66 fficacy, and randomised controlled trials of autologous stem-cell transplantation are underway.

67 bortezomib-based treatment before and after autologous stem cell transplantation (arm B) compared wi

68 Autologous stem cell transplantation as a platform for m

69 those ineligible for high-dose therapy with autologous stem-cell transplantation as well as supporti

70 corporated into conditioning regimens before autologous stem cell transplantation, as well as into po

71 the past decade as a result of incorporating autologous stem cell transplantation (ASCT) and novel ag

72 ansplant-eligible patients had the option of autologous stem cell transplantation (ASCT) consolidatio

73 eripheral stem cell mobilization followed by autologous stem cell transplantation (ASCT) feasible in

74 Patients undergoing autologous stem cell transplantation (ASCT) for multiple

75 L) who achieve complete response (CR) before autologous stem cell transplantation (ASCT) generally ha

76 Autologous stem cell transplantation (ASCT) has long bee

77 Autologous stem cell transplantation (ASCT) improves sur

78 lophosphamide 100 mg/kg (day -2) followed by autologous stem cell transplantation (ASCT) in 31 patien

79 D) as induction before high-dose therapy and autologous stem cell transplantation (ASCT) in patients

80 Autologous stem cell transplantation (ASCT) is superior

81 High-dose chemotherapy (HDT) plus autologous stem cell transplantation (ASCT) is the stand

82 High-dose chemoradiotherapy (HDT) with autologous stem cell transplantation (ASCT) is the treat

83 Patients with a duration response to a first autologous stem cell transplantation (ASCT) longer than

84 rge B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplantation (ASCT) or having re

85 se induction and up-front consolidation with autologous stem cell transplantation (ASCT) remain contr

86 PURPOSE OF REVIEW: Autologous stem cell transplantation (ASCT) represents t

87 ) with high-dose chemoradiotherapy (HDT) and autologous stem cell transplantation (ASCT) results in e

88 SLT) followed by high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to see if we

89 Autologous stem cell transplantation (ASCT) was retrospe

90 d that progression-free survival (PFS) after autologous stem cell transplantation (ASCT) was signific

91 patients (Deauville score </=2) proceeded to autologous stem cell transplantation (ASCT) whereas PET-

92 on therapy given after high-dose therapy and autologous stem cell transplantation (ASCT) with no cons

93 ents, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in youn

94 induction, intermediate-dose melphalan, and autologous stem cell transplantation (ASCT), followed by

95 eated first line with immunochemotherapy and autologous stem cell transplantation (ASCT), with or wit

96 te response (CR) rate postinduction and post-autologous stem cell transplantation (ASCT).

97 MS can be treated with high-dose therapy and autologous stem cell transplantation (ASCT).

98 d to high-dose chemoradiotherapy followed by autologous stem cell transplantation (ASCT).

99 w treatment with aggressive chemotherapy and autologous stem cell transplantation (ASCT).

100 lassification, and patients could proceed to autologous stem cell transplantation (ASCT).

101 e is now referred to discuss indications for autologous stem-cell transplantation (ASCT) and overall

102 High-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) are frequent

103 ) and acute myelogenous leukemia (AML) after autologous stem-cell transplantation (ASCT) are similar

104 e The benefit of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as first-lin

105 with relapsed multiple myeloma with salvage autologous stem-cell transplantation (ASCT) compared wit

106 rpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated

107 We hypothesized that in patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma

108 chemotherapy treatment program that included autologous stem-cell transplantation (ASCT) for patients

109 Autologous stem-cell transplantation (ASCT) has become a

110 a has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been

111 Autologous stem-cell transplantation (ASCT) has shown to

112 Patients with MCL who underwent autologous stem-cell transplantation (ASCT) in our insti

113 orelbine (BeGEV) as induction therapy before autologous stem-cell transplantation (ASCT) in patients

114 by up-front high-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) in PTCL, the

115 esized that gemcitabine-based therapy before autologous stem-cell transplantation (ASCT) is as effect

116 tients undergoing high-dose chemotherapy and autologous stem-cell transplantation (ASCT) is unclear.

117 104 study, lenalidomide versus placebo after autologous stem-cell transplantation (ASCT) was investig

118 y of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alter

119 ed and refractory HL who were ineligible for autologous stem-cell transplantation (ASCT), or for whom

120 r patients who are relapsed or refractory to autologous stem-cell transplantation (ASCT).

121 myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT).

122 emotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT).

123 obust biomarkers that predict outcomes after autologous stem-cell transplantation (ASCT).

124 e cured with high-dose chemoradiotherapy and autologous stem-cell transplantation (ASCT).

125 refractory (rel/ref) DEL or DHL who undergo autologous stem-cell transplantation (ASCT).

126 ide, cytarabine, and etoposide) supported by autologous stem-cell transplantation (ASCT).

127 (group III), or one HDAC/etoposide cycle and autologous stem-cell transplantation (ASCT; group IV).

128 ction therapy (n = 378) and at day 100 after autologous stem-cell transplantation (ASCT; n = 397) in

129 d potentially curative high-dose therapy and autologous stem-cell transplantations (ASCT) because of

130 es targeting tumor-associated antigens after autologous stem cell transplantations (ASCTs) might erad

131 ontrolled trials, adult patients who undergo autologous stem-cell transplantation at experienced cent

132 nisone (CHOP) and upfront consolidation with autologous stem cell transplantation (auto-SCT) have sho

133 neic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (auto-SCT).

134 igned to study intensive treatment including autologous stem cell transplantation (autoSCT) as part o

135 this study was to evaluate the outcome after autologous stem-cell transplantation (autoSCT) or alloge

136 Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce

137 eventeen patients acquired t-MDS/t-AML after autologous stem cell transplantation, but no unique patt

138 Autologous stem-cell transplantation can be performed sa

139 methasone-containing induction chemotherapy, autologous stem-cell transplantation, consolidation chem

140 We aimed to assess whether megatherapy with autologous stem-cell transplantation could increase even

141 We cross-referenced our autologous stem cell transplantation database with the D

142 h high-dose melphalan (HDM) chemotherapy and autologous stem cell transplantation, depending on iFISH

143 Immunomagnetic purging of PBSC for autologous stem-cell transplantation did not improve out

144 The efficacy of autologous stem-cell transplantation during the first re

145 Administration of cyclosporine A (CsA) after autologous stem cell transplantation elicits an autoimmu

146 nto account specific treatment goals, future autologous stem cell transplantation eligibility, and lo

147 combination with cytotoxic chemotherapy and autologous stem cell transplantation, especially for pat

148 mib, and dexamethasone (RVD) with or without autologous stem-cell transplantation, followed by lenali

149 tients underwent additional chemotherapy and autologous stem cell transplantation for bone marrow res

150 AT4 mRNA and protein deficiency occurs after autologous stem cell transplantation for lymphoma.

151 Severe immune deficiency follows autologous stem cell transplantation for multiple myelom

152 allogeneic (related and unrelated donor) and autologous stem cell transplantation for myelodysplasia.

153 itution, including antitumor immunity, after autologous stem cell transplantation for myeloma.

154 rapy before, and consolidation after, double autologous stem cell transplantation for newly diagnosed

155 Future studies may offer the opportunity for autologous stem cell transplantation for patients achiev

156 of aggressive HIV-non-Hodgkin lymphoma, and autologous stem cell transplantation for relapsed or ref

157 eceiving systemic chemotherapy or subsequent autologous stem cell transplantation for treatment of he

158 High-dose chemotherapy and autologous stem-cell transplantation for patients who me

159 endent predictor of poor survival rate after autologous stem-cell transplantation for relapsed or pri

160 h-dose etoposide and carboplatin followed by autologous stem-cell transplantations for germ cell tumo

161 bine, and melphalan or cyclophosphamide) and autologous stem cell transplantation from 2005 to 2009.

162 High-dose cytotoxic therapy followed by autologous stem cell transplantation has been proposed a

163 Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low

164 Early autologous stem cell transplantation has studies had hig

165 Autologous stem-cell transplantation has been shown to b

166 High-dose chemotherapy plus autologous stem-cell transplantation has been the standa

167 Patients whose disease relapses after autologous stem cell transplantation have poor prognosis

168 us HIV-negative lymphoma patients undergoing autologous stem cell transplantation have shown similar

169 is chemotherapy refractory or relapsed after autologous stem-cell transplantation have a grim prognos

170 s or high-dose therapy induction followed by autologous stem-cell transplantation have improved the o

171 High-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is suppo

172 y (thiotepa, busulfan, cyclophosphamide) and autologous stem cell transplantation (HDC-ASCT).

173 WBRT are high-dose chemotherapy supported by autologous stem cell transplantation (HDC/ASCT) or nonmy

174 immediately after high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT) in patie

175 who were eligible for high-dose chemotherapy-autologous stem-cell transplantation (HDCT-ASCT), were r

176 asome inhibitor, and high-dose melphalan and autologous stem cell transplantation (HDM/ASCT) followed

177 oidosis treated with high-dose melphalan and autologous stem-cell transplantation (HDM/SCT), the grea

178 er 1995 (introduction of high-dose melphalan/autologous stem cell transplantation [HDM-ASCT]) and 200

179 The incorporation of high-dose therapy/autologous stem cell transplantation (HDT/ASCT) and nove

180 mplete response (CR) after high-dose therapy/autologous stem cell transplantation (HDT/ASCT) is a sur

181 High-dose therapy with autologous stem-cell transplantation (HDT-ASCT) is now a

182 e been seen with high-dose chemotherapy plus autologous stem-cell transplantation (HDT-ASCT).

183 Roughly 50% of patients might be cured after autologous stem-cell transplantation; however, most pati

184 Autologous stem cell transplantation improved the outcom

185 Thalidomide maintenance therapy after autologous stem cell transplantation improved the qualit

186 Early autologous stem-cell transplantation improved progressio

187 consolidation with brentuximab vedotin after autologous stem-cell transplantation improved progressio

188 ce therapy with thalidomide-prednisone after autologous stem cell transplantation improves the durati

189 Myeloablative chemotherapy with autologous stem-cell transplantation improves the outcom

190 during the last several years that suggests autologous stem cell transplantation in first complete r

191 ed by immunotherapy-primed lymphocytes after autologous stem cell transplantation in hematologic mali

192 Early trials of high-dose therapy with autologous stem cell transplantation in mantle cell lymp

193 nsolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with pr

194 d consolidation with high-dose melphalan and autologous stem cell transplantation in the majority of

195 ved antimyeloma agents, along with combining autologous stem cell transplantation in the treatment of

196 The most common indication for autologous stem cell transplantation in the United State

197 The role for high-dose therapy and autologous stem-cell transplantation in mantle-cell lymp

198 , in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's ly

199 arabine, etoposide, and melphalan (BEAM) and autologous stem-cell transplantation in patients with no

200 Autologous stem cell transplantation, in the setting of

201 tegies to optimize the use of allogeneic and autologous stem cell transplantation include the develop

202 is Immune Suppression versus Transplant, and Autologous Stem cell Transplantation International Scler

203 The Autologous Stem Cell Transplantation International Scler

204 Autologous stem cell transplantation is used to rescue c

205 Autologous stem-cell transplantation is a common therapy

206 High-dose chemotherapy with autologous stem-cell transplantation is a standard treat

207 Autologous stem-cell transplantation is effective therap

208 ibritumomab tiuxetan to high-dose BEAM with autologous stem-cell transplantation is feasible and has

209 High-dose therapy followed by autologous stem-cell transplantation is standard of care

210 Autologous stem cell transplantation may be considered i

211 actory response, a consolidation by means of autologous stem cell transplantation may offer a greater

212 l-dose chemotherapy or high-dose therapy and autologous stem-cell transplantation may develop tMDS/AM

213 Autologous stem-cell transplantation may provide excelle

214 duction chemotherapy (n = 237), and after an autologous stem cell transplantation (n = 178).

215 Prior therapy included autologous stem cell transplantation (n = 42), 13-cis-RA

216 (melphalan, etoposide, and carboplatin) with autologous stem-cell transplantation (n=149) or to oral

217 Autologous stem cell transplantation offers a safe treat

218 better (>/= VGPR) after cycle 4 proceeded to autologous stem cell transplantation or continued treatm

219 ts--such as high-dose melphalan therapy plus autologous stem cell transplantation or regimens incorpo

220 espite maximal cytotoxic therapy with double autologous stem cell transplantation, outcome remains po

221 In comparison, autologous stem-cell transplantation patients rarely dem

222 After autologous stem cell transplantation, patients proceeded

223 after initial immunochemotherapy followed by autologous stem-cell transplantation, patients have rela

224 tients with non-Hodgkin lymphoma (NHL) after autologous stem-cell transplantation (PBSCT), patients w

225 al chemotherapy, intensive chemotherapy with autologous stem-cell transplantation, radiotherapy, intr

226 High-dose therapy and autologous stem cell transplantation remains an importan

227 High-dose therapy with supporting autologous stem-cell transplantation remains a controver

228 eparate univariate analysis of patients with autologous stem-cell transplantation revealed no differe

229 Autologous stem cell transplantation (SCT) has been an i

230 tients with multiple myeloma (MM) undergoing autologous stem cell transplantation (SCT).

231 recommended to decrease severe mucositis in autologous stem-cell transplantation (SCT) for hematolog

232 e, etoposide, and melphalan chemotherapy and autologous stem-cell transplantation (SCT) in patients w

233 toma when administered within 110 days after autologous stem-cell transplantation (SCT).

234 therapies (eg, intensive chemotherapy and/or autologous stem-cell transplantation [SCT]), baseline ou

235 select patients with chemosensitive disease, autologous stem cell transplantation should be considere

236 Autologous stem cell transplantation should be considere

237 of systemic sclerosis patients treated with autologous stem cell transplantation showed significant

238 restingly, 3 of 11 (27.2%) MM patients after autologous stem cell transplantations showed responses t

239 ventional doses, high-dose chemotherapy plus autologous stem-cell transplantation soon after the indu

240 r randomized treatment effect and subsequent autologous stem-cell transplantation, there was no diffe

241 cycle of induction chemotherapy followed by autologous stem-cell transplantation (transplantation gr

242 hole cohort, excluding 37 patients receiving autologous stem cell transplantation, was 3.1 year and i

243 classic Hodgkin's lymphoma who had undergone autologous stem-cell transplantation were randomly assig

244 cells isolated from lymphoma patients after autologous stem cell transplantation who have acquired S

245 bservation in 332 patients who had undergone autologous stem cell transplantation with melphalan 200

246 Responding patients were eligible for autologous stem cell transplantation with TAM6 or BEAM.

247 g per square meter of body-surface area plus autologous stem-cell transplantation with melphalan-pred

248 Patients underwent autologous stem-cell transplantation with PBSC as random

249 Eight patients subsequently had an autologous stem-cell transplantation with stem cells col

250 High-dose therapy with autologous stem cell transplantation (with melphalan 100

251 logeneic stem-cell transplantation; previous autologous stem-cell transplantation within 12 weeks of